Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.54p
   
  • Change Today:
      0.013p
  • 52 Week High: 1.85p
  • 52 Week Low: 0.52p
  • Currency: UK Pounds
  • Shares Issued: 429.62m
  • Volume: 327,031
  • Market Cap: £2.31m
  • Beta: 0.89

Evgen Pharma in talks about funding for Covid-19 clinical trial

By Michele Maatouk

Date: Friday 15 May 2020

LONDON (ShareCast) - (Sharecast News) - AIM-listed Evgen Pharma said on Friday that it is in talks with a potential source of funds that would help pay for a clinical trial in Covid-19 patients, in which it would provide support with its lead product, SFX-01.
The lead product from Evgen, which is a clinical stage drug development company focusing on the treatment of cancer and neurological conditions, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The statement was made in response to a rise in the share price in recent days.

"A further announcement will be made if these discussions are successful," it said.

At 1305 BST, the shares were up 27% at 14.48p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.54p
Change Today 0.013p
% Change 2.38 %
52 Week High 1.85p
52 Week Low 0.52p
Volume 327,031
Shares Issued 429.62m
Market Cap £2.31m
Beta 0.89

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
14.82% below the market average14.82% below the market average14.82% below the market average14.82% below the market average14.82% below the market average
72.00% above the sector average72.00% above the sector average72.00% above the sector average72.00% above the sector average72.00% above the sector average
Price Trend
86.02% below the market average86.02% below the market average86.02% below the market average86.02% below the market average86.02% below the market average
79.59% below the sector average79.59% below the sector average79.59% below the sector average79.59% below the sector average79.59% below the sector average
Income Not Available
Growth
17.33% below the market average17.33% below the market average17.33% below the market average17.33% below the market average17.33% below the market average
29.41% below the sector average29.41% below the sector average29.41% below the sector average29.41% below the sector average29.41% below the sector average

Theracryf Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
11:22 3,369 @ 0.52p
10:04 210,000 @ 0.53p
08:33 100,000 @ 0.55p
08:31 13,662 @ 0.55p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page